Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Steve Hilton & Spencer Pratt: Fixing California, Cheaper Gas, Ballot Fraud & CA Republicans 55 min · 23 Sep 2026 · All-In with Chamath, Jason, Sacks & Friedberg

Optics of Alastair Clarkson's brunt sacking | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

The Eminently Sensible Phil Davis | Whateley (23.09.26) 13 min · 23 Sep 2026 · Whateley

The impact of Zak Butters' homecoming | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded02 Mar 2026

Publisheraudiomedica.com ↗

Handlerec:19315677

Show notes

Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in